

**WHAT IS CLAIMED IS:**

1. An adenoviral vector for the selective expression of toxin gene in cancer cell, comprising a toxin gene operably linked to a promoter of a gene with undetectable expression in liver, wherein the expression of said toxin gene is reduced in liver cells.

2. The adenoviral vector of claim 1, wherein said promoter is cyclooxygenase-2 promoter.

3. The adenoviral vector of claim 2, wherein said cyclooxygenase-2 promoter is selected from the group consisting of cyclooxygenase-2 L (-1432/+59) and cyclooxygenase-2 M (-833/+59).

4. The adenoviral vector of claim 1, wherein said cancer cell is selected from the group consisting of gastrointestinal cancer cell and pancreatic cancer cell.

5. The adenoviral vector of claim 1, wherein said toxin gene is selected from the group consisting of the herpes simplex virus thymidine kinase gene, the cytosine deaminase gene and the purine nucleoside phosphorylase gene.

6. The adenoviral vector of claim 1, further comprises a RGD motif in the HI loop of the adenovirus-fiber protein.

7. A method of killing tumor cells with reduced liver toxicity in an individual, comprising the step of:

administering a therapeutically effective amount of adenoviral vector comprising a toxin gene operably linked to a promoter of a gene with undetectable expression in liver, wherein expression of said toxin gene is reduced in liver cells and expression of said toxin gene in tumor cells results in killing of said tumor cells.

8. The method of claim 7, wherein said administering is by intravenous injection.

5 9. The method of claim 7, wherein said tumor cells are selected from the group consisting of gastrointestinal cancer cells and pancreatic cancer cells.

10 10. The method of claim 7, wherein said promoter is cyclooxygenase-2 promoter.

15 11. The method of claim 10, wherein said cyclooxygenase-2 promoter is selected from the group consisting of cyclooxygenase-2 L (-1432/+59) and cyclooxygenase-2 M (-833/+59).

20 12. The method of claim 7, wherein said toxin gene is selected from the group consisting of the herpes simplex virus

thymidine kinase gene, the cytosine deaminase gene and the purine nucleoside phosphorylase gene.

5

13. The method of claim 7, wherein said toxin gene is the herpes simplex virus thymidine kinase gene, and further comprises a step of treating said individual with ganciclovir.

10  
15  
20  
25  
30  
35  
40  
45  
50  
55  
60  
65  
70  
75  
80  
85  
90  
95  
100  
105  
110  
115  
120  
125  
130  
135  
140  
145  
150  
155  
160  
165  
170  
175  
180  
185  
190  
195  
200  
205  
210  
215  
220  
225  
230  
235  
240  
245  
250  
255  
260  
265  
270  
275  
280  
285  
290  
295  
300  
305  
310  
315  
320  
325  
330  
335  
340  
345  
350  
355  
360  
365  
370  
375  
380  
385  
390  
395  
400  
405  
410  
415  
420  
425  
430  
435  
440  
445  
450  
455  
460  
465  
470  
475  
480  
485  
490  
495  
500

14. The method of claim 7, wherein said adenoviral vector further comprises a RGD motif in the HI loop of the adenovirus fiber protein.